Olema Pharmaceuticals (OLMA) News

Citigroup Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $59

Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $62 to $59.

Benzinga03:28

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Olema Pharmaceuticals Inc. (NASDAQ:OLMA) shares are trading lower on Tuesday as the company completed enrollment in its pivotal Phase 3 OPERA-01 trial, with top-line data now expected in the first

Benzinga02:27

Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Damora Therapeutics (DMRA)

TipRanksAug 11 22:50

A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $20 to $59

On Aug 11, major Wall Street analysts update their ratings for $Olema Pharmaceuticals(OLMA.US)$, with price targets ranging from $20 to $59.Goldman Sachs analyst Richard Law CFA maintains with a buy

Futu NewsAug 11 21:00

HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $36

HC Wainwright & Co. analyst Emily Bodnar maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from $38 to $36.

BenzingaAug 11 20:38

OppFi Posts Downbeat Q2 Earnings, Joins Upwork, Rocket Lab And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.1% on Tuesday.Shares of OppFi Inc (NYSE:OPFI) fell sharply in pre-market trading after the company reported

BenzingaAug 11 20:04

Olema Pharmaceuticals (OLMA) Receives a Buy From Goldman Sachs

TipRanksAug 11 19:35

Piper Sandler Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)

TipRanksAug 11 18:56

Tyler Van Buren Reiterates Buy on Olema, Citing Palazestrant's Late-Stage Differentiation and Multiple Value-Creating Catalysts

TipRanksAug 11 14:45

Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target Maintained

TipRanksAug 11 11:35

Olema Pharmaceuticals Q2 Loss Widens

Olema Pharmaceuticals (OLMA) reported a Q2 net loss late Monday of $0.61 per diluted share, widening from a loss of $0.51 a year earlier.Analysts polled by FactSet expected a loss of $0.55.As of

MT NewswiresAug 11 05:32

Express News | Olema Pharmaceuticals, - Completes Enrollment in Phase 3 Opera-01 Trial; Top-Line Data Expected Q1 2027

BreakingsAug 11 04:47

Olema Pharmaceuticals Q2 EPS $(0.61) Misses $(0.55) Estimate

Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.55) by 10.91 percent. This is a 19.61 percent decrease over

BenzingaAug 11 04:29

10-Q: Olema Pharmaceuticals | 10-Q: Q2 2026 Earnings Report

SECAug 11 04:11

8-K: Olema Pharmaceuticals | 8-K: Olema Oncology Reports Second Quarter 2026 Financial and Operating Results

SECAug 11 04:06

Express News | Olema Pharmaceuticals Q2 Income From Operations USD -67.179 Million

BreakingsAug 11 04:01

U.S. Earnings Preview: After Market Close Aug. 7

This article was automatically generated by Dow Jones using technology from Automated Insights. The following companies are among those expected to report their latest financial results after the

Dow JonesAug 8 03:30

Waste Connections, Entergy, Bj's, Olema, Tenet Insider Shock

TipRanksAug 1 21:01

Olema Pharma Insider Makes a Major Move With a Six-Figure Stock Sale

TipRanksJul 28 10:00

12 Health Care Stocks Moving In Monday's After-Market Session

GainersGossamer Bio (NASDAQ:GOSS) shares rose 28.8% to $0.26 during Monday's after-market session. The company's market cap stands at $66.4 million. ProMIS Neurosciences (NASDAQ:PMN) shares

BenzingaJul 28 05:06